OJJAARA momelotinib

Drug Class

JAK1/JAK2 and ACVR1 inhibitor

Mechanism

Inhibits JAK1, JAK2, and ACVR1 (ALK2), reducing cytokine-mediated signaling and lowering hepcidin levels to address anemia and splenomegaly.

Approved Indication

Treatment of intermediate or high-risk myelofibrosis (MF), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis, in adults with anemia.

What This Means For Patients

OJJAARA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2023) — Sources
• EMA — Approved (2024) — Sources

Pivotal Clinical Evidence

• MOMENTUM — Verstovsek et al., Lancet 2023 (NCT04173494) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218025s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/omjjara